1.Immune Checkpoints Mediate Tumor Immune Regulation through Metabolic Pathways.
Weiguang DU ; Xiyang TANG ; Yulong ZHOU ; Mengchao LI ; Ze JIN ; Jiaqi DOU ; Jinbo ZHAO
Chinese Journal of Lung Cancer 2025;28(3):213-220
Immune checkpoints include a series of receptor-ligand pairs that play a key role in the proliferation, activation, and immune regulatory responses of immune cells. Although immune checkpoint inhibitors (ICIs), such as programmed death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have achieved good therapeutic effects in clinical practice, some patients still experience ineffective treatment and immune resistance. A large amount of evidence has shown that immune checkpoint proteins are related to cell metabolism during immune regulation. On the one hand, immune checkpoints connect to alter the metabolic reprogramming of tumor cells to compete for nutrients required by immune cells. On the other hand, immune checkpoints regulate the metabolic pathways of immune cells, such as phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) to affect the activation of immune cells. Based on a review of the literature, this article reviews the mechanisms by which PD-1, CTLA-4, T cell immunoreceptor with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), cluster of differentiation 47 (CD47), and indoleamine 2,3-dioxygenase 1 (IDO1) regulate cell metabolic reprogramming, and looks forward to whether targeting the ligand-receptor pairs of immune checkpoints in a "dual regulation" manner and inhibiting metabolic pathways can effectively solve the problem of tumor immune resistance.
.
Humans
;
Neoplasms/genetics*
;
Metabolic Networks and Pathways/immunology*
;
Animals
;
Immune Checkpoint Inhibitors/pharmacology*
2.Predictive value of a model based on clinical features and plasma biomarkers for AF after pacemaker implantation surgery
Mengchao JIN ; Hui LI ; Siliang PENG ; Xinru GUO
Chinese Journal of Geriatric Heart Brain and Vessel Diseases 2025;27(6):742-746
Objective To construct a prediction model for atrial fibrillation(AF)after pacemaker implantation based on clinical features and plasma atrial natriuretic peptide(ANP)and brain na-triuretic peptide(BNP).Methods A retrospective analysis was conducted on 242 patients under-going pacemaker implantation in our department from January 2020 to October 2023.According to the occurrence of postoperative AF or not,they were divided into an AF group(61 cases)and a non-AF group(181 cases).The risk factors of AF after pacemaker implantation were analyzed,and a risk prediction model of AF after pacemaker implantation was constructed based on clinical features and plasma ANP and BNP levels.Results The AF group had significantly advanced age,larger proportions of hypertension and coronary heart disease,larger left ventricular diameter,and higher ANP,BNP,IL-6 and IL-8 levels,but lower proportion of using calcium antagonists when compared with the non-AF group(P<0.01).Binary logistic regression analysis showed that hy-pertension,coronary heart disease,ANP,BNP and IL-6 were risk factors(P<0.05,P<0.01),and taking calcium antagonists was protective factor for AF after pacemaker implantation(P<0.05).Hosmer Lemeshow fitting test indicated the model had a good fitness(x2=7.264,P=0.508).ROC curve analysis showed that the area under curve(AUC)value of the risk model for AF after pacemaker implantation in the training set was 0.826(95%CI:0.768-0.884),with an accuracy of 79.3%(192/242),and the AUC value of the model in the validation set was 0.835(95%CI:0.733-0.938).Conclusion Our AF prediction model based on clinical features and plasma ANP and BNP had good performance,and can provide auxiliary reference in predicting AF in patients undergoing pacemaker implantation.
3.Predictive value of a model based on clinical features and plasma biomarkers for AF after pacemaker implantation surgery
Mengchao JIN ; Hui LI ; Siliang PENG ; Xinru GUO
Chinese Journal of Geriatric Heart Brain and Vessel Diseases 2025;27(6):742-746
Objective To construct a prediction model for atrial fibrillation(AF)after pacemaker implantation based on clinical features and plasma atrial natriuretic peptide(ANP)and brain na-triuretic peptide(BNP).Methods A retrospective analysis was conducted on 242 patients under-going pacemaker implantation in our department from January 2020 to October 2023.According to the occurrence of postoperative AF or not,they were divided into an AF group(61 cases)and a non-AF group(181 cases).The risk factors of AF after pacemaker implantation were analyzed,and a risk prediction model of AF after pacemaker implantation was constructed based on clinical features and plasma ANP and BNP levels.Results The AF group had significantly advanced age,larger proportions of hypertension and coronary heart disease,larger left ventricular diameter,and higher ANP,BNP,IL-6 and IL-8 levels,but lower proportion of using calcium antagonists when compared with the non-AF group(P<0.01).Binary logistic regression analysis showed that hy-pertension,coronary heart disease,ANP,BNP and IL-6 were risk factors(P<0.05,P<0.01),and taking calcium antagonists was protective factor for AF after pacemaker implantation(P<0.05).Hosmer Lemeshow fitting test indicated the model had a good fitness(x2=7.264,P=0.508).ROC curve analysis showed that the area under curve(AUC)value of the risk model for AF after pacemaker implantation in the training set was 0.826(95%CI:0.768-0.884),with an accuracy of 79.3%(192/242),and the AUC value of the model in the validation set was 0.835(95%CI:0.733-0.938).Conclusion Our AF prediction model based on clinical features and plasma ANP and BNP had good performance,and can provide auxiliary reference in predicting AF in patients undergoing pacemaker implantation.
4.Anti-COVID-19 mechanism of Anoectochilus roxburghii liquid based on network pharmacology and molecular docking
Jin ZHU ; Yan-bin WU ; De-fu HUANG ; Bing-ke BAI ; Xu-hui HE ; Dan JIA ; Cheng-jian ZHENG
Acta Pharmaceutica Sinica 2024;59(3):633-642
italic>Anoectochilus roxburghii liquid (spray, a hospital preparation of Wu Mengchao Hepatobiliary Hospital of Fujian Medical University) has shown a good clinical treatment effect during the COVID-19 pandemic, but its material basis and mechanism of action are still unclear. In this study, network pharmacology and molecular docking methods were used to predict the molecular mechanism of
5.The way of thinking decides exit and the innovation leads future: practice and implementation of Academician Lau Wan Yee's research ideas
Weiping ZHOU ; Feng SHEN ; Shuqun CHENG ; Tian YANG ; Gang HUANG ; Siyuan FU ; Jin ZHANG ; Kui WANG ; Dong WU ; Mengchao WU
Chinese Journal of Digestive Surgery 2018;17(1):51-54
Through analysis of Lau Wan Yee's published papers,monographs,conference speeches,research designs / revisions for major hospitals in China,combined with analysis of articles revised by Academician Lau in the Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University for the past decade,authors came up with 9 points in Academician Lau's research ideas.Academician Lau has played a huge and leading role in improving clinical skills and scientific research levels,as well as in development and internationalization of hepatobiliary and pancreatic surgery in China.To summarize the research ideas of Lau is of great importance to the future generations of surgeons.
6.Treatment of Murine Allergic Contact Dermatitis with CTLA4-Ig
Qian ZHOU ; Geng KOU ; Weizhu QIAN ; Hao WANG ; Yanjun LIU ; Xiaoyun WANG ; Shuichuan SONG ; Jun JIN ; Xiaodong LI ; Mengchao WU ; Yajun GUO ; Lieping CHEN
Chinese Journal of Dermatology 1995;0(04):-
Objective To study the effects of CTLA4-Ig on mu rine allergic contact dermatitis.Methods Mice were exposed to DNFB to induce allergic contact dermatitis and were i njected with CTLA4-Ig.Ear swelling was measured 24h after antigen challenge.Splenocytes from treated mice were assayed for their ability to prolif erate in response to DNFB or FITC stimulation in vitro.Results Profound inhibition of contact hypersensitivity response(CHS )was shown by 69.7%in mice treated with CTLA4-Ig compared with mice treate d with PBS control.CT-LA4-Ig-treated mice displayed DNFB-specific tolerance,but exhibited a vigorous immune response to FITC when re-sensitizing 14days after the fir st challenge.Adoptive transfer of l ymphocytes from CTLA4-Ig-treated mice could induce inhibition of CHS in recipien t mice.Conclusions CTLA4-Ig can inhibit CHS by blocking B7/CD28co-stimulatory pathway,which provides a new way to suppress typeⅣallergic reaction.[

Result Analysis
Print
Save
E-mail